Erika Resetkova, M.D., PhD.
Department of Anatomical Pathology, Division of Pathology-Lab Medicine Div
About Dr. Resetkova
Dr. Resetkova is a Professor in the Section of Breast Pathology of the Department of Pathology at the University MD Anderson Cancer Center in Houston, TX. She is board certified in Anatomic and Clinical Pathology with subspecialty certification in Cytopathology. Dr. Resetkova received her medical degree from the Comenius University in Bratislava, Slovakia where she also completed her PhD and residency training in internal medicine. Her postdoctoral work in the University of Toronto, Canada focused on studies of immunologic abnormalities in autoimmune thyroid disorders. She completed her pathology residency training in Anatomic and Clinical Pathology at the New York Weill Cornell Medical Center, New York, NY, and fellowships in Breast Pathology and Cytopathology at the U. T. MD Anderson Cancer Center in Houston. She provides comprehensive clinical services in breast pathology with extensive intraoperative breast evaluation and frozen sections, and outside referral and consultation services. She participates in clinical research and clinical trials and is attentive to implementation of digital pathology in the department. She has clinical and research interests in breast cancer and precancerous lesions with specific emphasis on triple negative tumors and inflammatory carcinoma as well as a broad range of preneoplastic lesions. She is nationally and internationally recognized for her academic work. Dr. Resetkova has authored close to 90 research articles and many book chapters. She is frequently an invited lecturer and teaches and mentors residents, fellows, and junior faculty members.
Read More
Present Title & Affiliation
Primary Appointment
Professor, Department of Pathology/Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1989 | Institute of Experimental Endocrinology, Bratislava, SVK, PHD, Physiology and Pathophysiology |
| 1984 | Medical Faculty of Comenius University, Bratislava, SVK, MD, Medicine |
Postgraduate Training
| 2003-2004 | Fellowship in Cytopathology, Department of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2002-2003 | Fellowship in Breast Pathology, Department of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2001-2001 | Fellowship in Breast Pathology, Prof. Paul P. Rosen, Department of Pathology and Laboratory Medicine, New York Weill Cornell Medical Center, New York, NY |
| 1999-2002 | Residency in Anatomic and Clinical Pathology, Department of Pathology and Laboratory Medicine, New York Weill Cornell Medical Center, New York, NY |
| 1998-1999 | Residency in Anatomic and Clinical Pathology, Department of Pathology and Laboratory Medicine, Strong Memorial Hospital, University of Rochester, Rochester, NY |
| 1996-1997 | Postdoctoral Fellowship, Department of Immunology and Rheumatology, Strong Memorial Hospital, University of Rochester, Rochester, NY |
| 1990-1996 | Postdoctoral Fellowship, Endocrinology Research Institute, University of Toronto, Toronto |
| 1986-1990 | Residency in Internal Medicine, Institute of Postdoctoral Education, Bratislava |
Board Certifications
| 2004 | The American Board of Pathology, Cytopathology Board, USA |
| 2002 | The American Board of Pathology, AP/CP Pathology Board, USA |
| 1990 | Internal Medicine, Slovakia |
Honors & Awards
| 2017 | Awarded participation and completed in Heart of Leadership Program, MD Anderson Cancer Center |
| 2009 | Awarded participation in Early Career Women Faculty Professional Development Seminar, Ritz Carlton Hotel, July 11-14 |
Selected Publications
Peer-Reviewed Articles
- Wanis KN, Goetz L, So A, Glencer AC, Sun SX, Teshome M, Resetkova E, Hwang RF, Hunt KK, Candelaria RP, Huo L, Singh P. ASO Visual Abstract: The Prevalence of Sentinel Lymph Node Positivity and Implications for the Utility of Frozen Section Diagnosis Following Neoadjuvant Systemic Therapy in Patients with Clinically Node-Negative HER2-Positive or Triple-Negative Breast Cancer. Ann Surg Oncol. e-Pub 2024. PMID: 39107599.
- Wanis KN, Goetz L, So A, Glencer AC, Sun SX, Teshome M, Resetkova E, Hwang RF, Hunt KK, Candelaria RP, Huo L, Singh P. The Prevalence of Sentinel Lymph Node Positivity and Implications for the Utility of Frozen Section Diagnosis Following Neoadjuvant Systemic Therapy in Patients with Clinically Node-Negative HER2-Positive or Triple-Negative Breast Cancer. Ann Surg Oncol. e-Pub 2024. PMID: 39048903.
- Shen T, Zhao J, Zhao M, Taggart MW, Ramalingam P, Gong Y, Wu Y, Liu H, Zhang J, Resetkova E, Wang WL, Ding Q, Huo L, Yoon E. Unusual Staining of Immunohistochemical Markers PAX8 and CDX2 in Breast Carcinoma: A Potential Diagnostic Pitfall. Hum Pathol. e-Pub 2022. PMID: 35417734.
- Zhou P, Chang N, Abraham SC, Albarracin CT, Huo L, Chen H, Ding Q, Resetkova E, Middleton LP, Sahin AA, Bu H, Wu Y. Metastatic non-Hematopoietic Neoplasms to the Breast: A Study of 238 Cases. Hum Pathol. e-Pub 2022. PMID: 35447141.
- Van Bockstal MR, François A, Altinay S, Arnould L, Balkenhol M, Broeckx G, Burguès O, Colpaert C, Dedeurwaerdere F, Dessauvagie B, Duwel V, Floris G, Fox S, Gerosa C, Hastir D, Jaffer S, Kurpershoek E, Lacroix-Triki M, Laka A, Lambein K, MacGrogan GM, Marchiò C, Martin Martinez MD, Nofech-Mozes S, Peeters D, Ravarino A, Reisenbichler E, Resetkova E, Sanati S, Schelfhout AM, Schelfhout V, Shaaban A, Sinke R, Stanciu-Pop CM, van Deurzen CHM, Van de Vijver KK, Van Rompuy AS, Vincent-Salomon A, Wen HY, Wong S, Bouzin C, Galant C. Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. Mod Pathol. e-Pub 2021. PMID: 34218258.
- Huang X, Ding Q, Guo H, Gong Y, Zhao J, Zhao M, Sui D, Wu Y, Chen H, Liu H, Zhang J, Resetkova E, Moulder SL, Wang WL, Huo L. Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma. Hum Pathol 108:42-50, 2021. e-Pub 2020. PMID: 33221342.
- Guo H, Ding Q, Gong Y, Gilcrease MZ, Zhao M, Zhao J, Sui D, Wu Y, Chen H, Liu H, Zhang J, Resetkova E, Moulder SL, Wang WL, Huo L. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors. Breast Cancer Res 22(1):69, 2020. e-Pub 2020. PMID: 32576238.
- Boros M, Resetkova E, Molnar C, Podoleanu C, Dema A, Olinca M, Alvarado-Cabrero I, Buiga R, Stolnicu S. Analysis of Clinical-Pathological Data with Impact on Overall Survival in Male Breast Carcinoma: An International Multi-Institutional Study of 217 Cases. Chirurgia (Bucur) 115(3):323-333, 2020. PMID: 32614287.
- Dano H, Altinay S, Arnould L, Bletard N, Colpaert C, Dedeurwaerdere F, Dessauvagie B, Duwel V, Floris G, Fox S, Gerosa C, Jaffer S, Kurpershoek E, Lacroix-Triki M, Laka A, Lambein K, MacGrogan GM, Marchió C, Martinez DM, Nofech-Mozes S, Peeters D, Ravarino A, Reisenbichler E, Resetkova E, Sanati S, Schelfhout AM, Schelfhout V, Shaaban AM, Sinke R, Stanciu-Pop CM, Stobbe C, van Deurzen CHM, Van de Vijver K, Van Rompuy AS, Verschuere S, Vincent-Salomon A, Wen H, Bouzin C, Galant C, Van Bockstal MR. Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. Mod Pathol 33(3):354-366, 2020. e-Pub 2019. PMID: 31534203.
- Wang S, Oh DY, Leventaki V, Drakos E, Zhang R, Sahin AA, Resetkova E, Edgerton ME, Wu W, Claret FX. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer. Cancer Lett 465:12-23, 2019. e-Pub 2019. PMID: 31473252.
- Moseley TW, Shah SS, Nguyen CV, Rosenblat J, Resetkova E, Sneige N, Brandt KR, Huo L. Clinical Management of Mucocele-Like Lesions of the Breast with Limited or no Epithelial Atypia on Core Biopsy: Experience from Two Institutions. Ann Surg Oncol. e-Pub 2019. PMID: 31187364.
- Stolnicu S, Moncea D, Dema A, Geambasu S, Moldovan C, Comanescu M, Voidazan S, Georgescu R, Alvarado-Cabrero I, Resetkova E, Buiga R. Androgen Receptor (AR) Expression in Invasive Male Breast Carcinoma (MBC): An International Multi-Institutional Review of 168 Cases Emphasizing the Potential Use of AR as a Therapeutic Target. Appl Immunohistochem Mol Morphol 25(2):e18-e20, 2017. PMID: 28177976.
- Adrada BE, Huo L, Lane DL, Arribas EM, Resetkova E, Yang W. Histopathologic Correlation of Residual Mammographic Microcalcifications After Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer. Ann Surg Oncol 22(4):1111-7, 2015. e-Pub 2014. PMID: 25287438.
- Huo L, Gong Y, Guo M, Gilcrease MZ, Wu Y, Zhang H, Zhang J, Resetkova E, Hunt KK, Deavers MT. GATA-3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry. Histopathology. e-Pub 2015. PMID: 25564996.
- Schuh F, Biazús JV, Resetkova E, Benfica CZ, Ventura Ade F, Uchoa D, Graudenz M, Edelweiss MI. Histopathological grading of breast ductal carcinoma In Situ: validation of a web-based survey through intra-observer reproducibility analysis. Diagn Pathol 10:93, 2015. e-Pub 2015. PMID: 26159429.
- Burch-Smith R, Tannir NM, Resetkova E, Tamboli P, Rao P. Collision tumor of the kidney composed of clear cell carcinoma and collecting duct carcinoma: report of a case with unusual morphology and clinical follow up. Chin J Cancer. e-Pub 2014. PMID: 24589208.
- Huo L, Zhang J, Gilcrease MZ, Gong Y, Wu Y, Zhang H, Resetkova E, Hunt KK, Deavers MT. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer. Histopathology 62(2):267-74, 2013. e-Pub 2012. PMID: 22963676.
- Resetkova E. A Pictorial Journey Through Variants of Ductal Carcinoma in Situ (DCIS) and DCIS Mimickers. Clin Breast Cancer 12(5):347-63, 2012. PMID: 23040003.
- Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, Albarracin CT. Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol 36(9):1353-8, 2012. PMID: 22895267.
- Marian C, Boila A, Soanca D, Malau M, Podeanu DM, Resetkova E, Stolnicu S. Malignant transformation of adenomyoepithelioma of the breast by a monophasic population: a report of two cases and review of literature. APMIS. e-Pub 2012. PMID: 23030630.
- Tian Z, Wei B, Tang F, Wei W, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Middleton L, Sahin A, Xing Y, Hunt KK, Chen J, Bu H, Rashid A, Abraham SC, Wu Y. Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol 42(8):1169-77, 2011. e-Pub 2011. PMID: 21334720.
- Tang F, Wei B, Tian Z, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Zhang H, Sahin A, Chen J, Bu H, Abraham S, Wu Y. Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. Histopathology 59(1):106-15, 2011. e-Pub 2011. PMID: 21668471.
- Lee YS, Mathew J, Dogan BE, Resetkova E, Huo L, Yang WT. Imaging Features of Micropapillary DCIS: Correlation with Clinical and Histopathological Findings. Acad Radiol 18(7):797-803, 2011. e-Pub 2011. PMID: 21419669.
- Resetkova E, Edelweiss M, Albarracin CT, Yang WT. Management of radial sclerosing lesions of the breast diagnosed using percutaneous vacuum-assisted core needle biopsy: recommendations for excision based on seven years' of experience at a single institution. Breast Cancer Res Treat 127(2):335-43, 2011. e-Pub 2008. PMID: 18626769.
- Resetkova E, Khazai L, Albarracin CT, Arribas E. Clinical and radiologic data and core needle biopsy findings should dictate management of cellular fibroepithelial tumors of the breast. Breast J 16(6):573-80, 2010. PMID: 21070433.
- Schuh F, Biazús JV, Resetkova E, Benfica CZ, Edelweiss MI. Reproducibility of three classification systems of ductal carcinoma in situ of the breast using a web-based survey. Pathol Res Pract 206(10):705-11, 2010. e-Pub 2010. PMID: 20663616.
- Mehta R, Jain RK, Sneige N, Badve S, Resetkova E. Expression of high-molecular-weight cytokeratin (34betaE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast. J Clin Pathol 63(8):744-7, 2010. PMID: 20702478.
- Resetkova E, Reis-Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H, Badve S. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat 123(1):97-108, 2010. e-Pub 2009. PMID: 19911270.
- Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez Angulo AM, Dawood S, Resetkova E, Le-Petross HT, Yang WT. Retrospective Study of 18F-FDG PET/CT in the Diagnosis of Inflammatory Breast Cancer: Preliminary Data. J Nucl Med 50(2):231-238, 2009. e-Pub 2009. PMID: 19164229.
- Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT. Loss of Annexin A1 Expression in Breast Cancer Progression. Appl Immunohistochem Mol Morphol 16(6):530-4, 2008. PMID: 18776816.
- Dawood S, Resetkova E, Gonzalez-Angulo AM. Trastuzumab administration associated with change in HER2 status. Clin Breast Cancer 8(4):366-9, 2008. PMID: 18757266.
- Yang WT, Le-Petross HT, Macapinlac H, Carkaci S, Gonzalez-Angulo AM, Dawood S, Resetkova E, Hortobagyi GN, Cristofanilli M. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat 109(3):417-426, 2008. e-Pub 2007. PMID: 17653852.
- Ferreira M, Albarracin CT, Resetkova E. Pseudoangiomatous stromal hyperplasia. (PASH) tumors: A clinicopathologic study of 26 cases. Mod Path 21(2):201-207, 2008.
- Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT.. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: Association with poor outcome. Cancer 109(4):658-667, 2007. PMID: 17211865.
Abstracts
- Ye Q, Klippel D, Albarracin C, Chen H, Contreras A, Ding Q, Huo L, Khazai L, Middleton L, Resetkova E, Sahin A, Sun H, Sweeney K, Symmans W, Wu Y, Krishnamurthy S. A Prospective Study of Real Time Whole Slide Imaging of Frozen Sections for Intraoperative Evaluation of Axillary Sentinel Lymph Nodes in Breast Cancer. Mod Pathol 104(3):S321-22, 2024.
- Sun H, Huo L, Sweeney K, Resetkova E, Chai D, Chen H, Albarracin C, Wu Y, Ding Q. SMARCA4/BRG1 Deficiency in Breast Carcinoma by Immunohistochemistry Study. Mod Pathol 104(3):S274-75, 2024.
- Yoon E, Wang G, Wu Y, Chen H, Albarracin C, Resetkova E, Krishnamurthy S, Salisbury T, Sahin A, Ding Q. Expression of TRPS1, SOX10 and GATA3 in Triple Negative Invasive Ductal and Lobular Carcinomas. USCAP 111th Annual Meeting 2022, 2022. e-Pub 2022.
- Van Bokstal MR, Dano H, Altinay S, Arnould L, Bletard N, Colpaert C, Dedeurwaerdere F, Dessauvagie B, Duwel V, Floris G, Fox S, Gerosa C, Jaffer S, Kurpershoek E, Lacroix-Triki M, Laka A, Lambien K, MacGrogan GM, Marchio C, Martinez D, Nofech-Mozes S, Peeters D, Ravarino A, Reisenbichler E, Resetkova E, Sanati S, Schelfhout A,Schelfhout V, Shaaban AM, Sinke R, Stanciu-Pop CM, Stobbe C, Van Deurzen CHM, Van de Vijver K Van Rompuy A, Verschuere S, Vincent-Salomon A, Wen H, Bouzin C, Galant C.. Upfront dichotomous assessment of ductal carcinoma in situ of the breast to reduce inter-observer variability: the DCISion study. San Antonio Breast cancer Symposium, 2019. e-Pub 2019.
- Resetkova E.. Breast implant capsule-associated pathology:from " common" to "rare "to "unique". 30th European Congress of Pathology, Bilbao, Spain, 2018.
- Resetkova E. Breast Implant Capsule-Associated Pathology: From "Common" to "Rare" to "Unique" - 35th Annual Miami Breast Conference. Miami, FL, 2018.
- Y. Li, R. Luthra, J. Hu, L. Shen, RR Broadus, Resetkova E, Y Wu, CT Albarracin. Mir-182*, mir-183, and mir-143 are deregulated in endometrial endometroid cancers. Mod Pathol 30(S2):459A, 2017.
- Albarracin C, Dhamne S, Arun B, Ward K, Wu Y, Rosen D, Cui X, Resetkova E, Duan X, Chen H, Bedrosian I, Barrera A,. BRCA1 and BRCA2-Associated Breast Cancers Demonstrate Distinct Histopathologic Features, Biomarker Expression Patterns and Molecular Subtypes. Mod Pathol 29(2):39A, 2016.
- Stolnicu S, Moncea D, Dema A, Buiga R, Moldovan C, Georgescu R, Toganel C, Voidazan S, Resetkova E, Comanescu M, Alvarado-Cabrero I. Analysis of Clinical-Pathological Data with Impact on Overall Survival (OS) in Male Breast Carcinoma: An International Multi-Institutional Study of 220 Cases. Mod Pathol 29(2):74A, 2016.
- Stolnicu S, Moncea D, Dema A, Geambasu S, Moldovan M, Comanescu S, Voidizan R, Georgescu R, Alvarado-Cabrero I, Resetkova E, Buiga R. Androgen receptor (AR) expression in invasive male breast carcinoma (MBC): An international multi-institutional review of 168 cases. Virchows Arch 469(Suppl 1):S46, PS-01-004, 2016.
- Dhamne S, Sneige N, Rosen D, Bedrosian I, Resetkova E, Wu Y, Arun B, Albarracin C. High nuclear expression of p27 correlates with luminal A molecular subtype of ductal carcinoma in situ of breast. Mod Pathology 27(2):45A, 2014.
- Resetkova E, Padula A. IgG4-related sclerosing mastitis(IgG4-RSM) of the breast: An uncommon entity and diagnostic challenge on core biopsy (CB). Mod Pathol 27(2):77A, 2014.
- Resetkova E, Padula, A. IgG4-Related Sclerosing Mastitis(IgG4-RSM) of the Breast. Diagnostic Conundrum on Core Needle Biopsy (CB) Specimens. Virch Arch, 2014.
- Aquil B, Arun B, Sneige N, Barrera-Gutierez AM, Rosen D, Abrahams S, Resetkova E, Wu Y, Albarracin CT. Histology of breast cancer in patients with Lynch syndrome. Mod Pathol 26(Suppl 2):27A, 2013.
- Duan X, Gullet A, Sneige N, Rosen D, Resetkova E, Ersahin C, Wu Y, Bedrosian I, Albarracin CT. Clinicopathologic features of male paget disease of breast: 11 cases from a single institution. Mod Pathol 26(Suppl 2):37A, 2013.
- Resetkova E, Sneige N. Proposal for a new classification of "equivocal" fibroepithelial lesions (FELs). Mod Pathol 26((Suppl 2)):482A, 2013.
- Resetkova E. Utility of immunoperoxidase studies in improving diagnosis of metastases in body cavity effusions. Acta Cytologica 57(Suppl 1):1-172, 102P, 2013.
- Duan X, Gullet A, Sneige N, Resetkova E, Ersahin C, Wu Y, Bedrosian I, Albarracin C.. Male mammary Paget disease: Ten cases from a single institute. Virch Arch 463(Suppl:PS-17-090), 2013.
- Gullett AE, Prieto VG, Lopez K, Arun B, Bedrosian I, Resetkova E, Wu Y, Albarracin CT. Type of mammary Paget disease is associated with disease free survival. Mod Pathol 23(Suppl 1):115A, 2012.
- Gullett AE, Sneige N, Prieto VG, Kelly CM, Bassett RL, Resetkova E, Duan, X, Li Y, Rosen D, Wu Y, Huo L, Klein K, Bedrosian I, Arun B, Hunt K, Albarracin CT. Pathological and clinical characteristics of mammary Paget disease: 25-year experience from a major tertiary referral center. Mod Pathol 25(Suppl 2):121A, 2012.
- Duan X, Sneige NE, Gullett AE, Prieto VG, Resetkova E, Albarracin CT. Minimally invasive Paget disease of breast: An under-recognized entity in the breast. Mod Pathol 24(Suppl 1):146, 2011.
- Albarracin CT, Gullet A, Prieto V, Kelly C, Duan X, Bassett R, Klein K, Resetkova E, Rosen DG, Wu Y, Sneige N. Histopathologic charateristics and disease-free survival of mammary Paget disease?. Virchows Arch 459((Suppl):S3), 2011.
- Adrada B, Lane D, Arribas EM, Resetkova E, Huo L, Yang WT. The significance of residual mammographic calcifications after neoadjuvant therapy (Scientific Presentation). Radiological Society of North America (RSNA), 2010.
- Wei B, Tian F, Wei W, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Middleton LP, Sahin A, Chen J, Abraham SC, Wu, Y. Prognostic factors of primary invasive mammary neuroendocrine carcinoma: clinicopathologic analysis of 74 cases. Mod Pathol 23(Suppl 1):77A, 2010.
- Resetkova E, Albarracin C, Arribas E, Sneige N. Careful initial clinical-radiologic-pathologic correlation should dictate clinical management of equivocal fibroepithelial lesions diagnosed on core biopsy. Vichows Arch 457(OP002):149, 2010.
- Chang KN, Resetkova E , Huo L, Yang, WT. Imaging-pathologic correlation in fat necrosis of the breast (Education Exhibit). Radiological Society of Noth American (RSNA), 2010.
- Resetkova E, Khazai L, Arribas E. Diagnosis of cellular fibroepithelial lesion of the breast by core biopsy: Guide to management based on clinical, radiologic, and pathologic correlation 6-year experience at a single institution. Breast Cancer Symposium Proceedings. Breast Cancer Symposium, San Francisco, California(Abstract 121), 2009.
- Ngyuen CV, Resetkova E, Huo L. Mucocele-like lesions of breast with no or minimal epithelial atypia on core biopsy: to excise or not?. Mod Pathol 22(Suppl 1):258A, 2009.
- Gullett AE, Duan X, Fuller GN, Brown R, Li Y, Luthra R, Wiseman W, Resetkova E, Yao H, Puduvali V, Wu Y, Bruner JM, Albarracin CT. Expression of annexin A1 and constitutive activation of the Akt/mTOR pathway in high-grade diffuse gliomas: a potential connection with S phase kinase-associated protein (Skp2) in glioma progression. Mod Pathol 22(Suppl 1):1492A, 2009.
- Albarracin CT, Siguake E, Whitman G, Yang WT, Resetkova E, Johnson MM, Ngyuen CV, Sneige N. Atypical and columnar cell lesions in breast needle biopsies for indeterminate microcalcifications: predictors of higher risk findings requiring surgical excision. 31st Annual San Antonio Breast Cancer Symposium,(Abs. 3004), 2008.
- Tang F, Gilcrease M, Albarracin CT, Huo L, Middleton LP, Resetkova E, Wu Y.. Invasive solid papillary carcinoma of the breast: A clinicopathologic analysis of 52 cases. Mod Pathol 21(Suppl 1, Abs. 2481), 2008.
- Albarracin C, Ricketts R, Willer S, Li Y, Huo L, Wu Y, Resetkova E. Differential expression of cytokeratins 903 and 5/6 antibodies in breast cancer tissue compared to adjacent benign epithelium. Histopathology 53(Suppl. 1):053, 2008.
- Resetkova E, Edelweiss M, Albarracin C, Yang W. Management of radial sclerosing lesions of the breast diagnosed using percutaneous vacuum assisted core biopsy: when excision is necessary?. Histopathology 53(Suppl. 1):133, 2008.
- Resetkova E, Thorat M, Badve S. Expression of ALDH1 (putative cancer stem cell marker) does not correlate with response to neoadjuvant chemotherapy (NATC) in breast carcinoma. Histopathology 53(Suppl. 1):134, 2008.
Patient Reviews
CV information above last modified August 07, 2024